In today’s ACT Brief, we examine how the CRA role is transforming alongside modern clinical trial technology, review the ...
In this Q&A, John Kirk, principal regulatory specialist at Veristat, explains how the FDA’s Commissioner’s National Priority ...
The FDA has granted accelerated approval to Otsuka’s Voyxact for adults with primary IgAN at risk of disease progression, ...
Novo Nordisk's 7.2 mg Wegovy injectable aims to enhance chronic weight management in adults with obesity, using an expedited ...
The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for the treatment of adult ...
With the right technology and support, CRAs can continue their evolution into powerful agents of trial success that bridge ...
In today’s ACT Brief, we examine how AI is being integrated into administrative workflows at investigative sites, highlight the FDA’s approval of the first gene therapy for adolescents and adults with ...
The FDA has approved Novartis’ Itvisma (onasemnogene abeparvovec-brve) for the treatment of adolescents two years and older, teens, and adults living with spinal muscular atrophy (SMA) with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback